1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Biofil Chemicals & Pharmaceuticals Ltd.

Biofil Chemicals & Pharmaceuticals Ltd.

28.16
INR
-1.59
(-5.34%)
0.30EPS
115.29P/E
563.56MMarket Cap
Biofil Chemicals & Pharmaceuticals Ltd.
BSE:BIOFILCHEM
(Bombay Stock Exchange)

Recent

price

28.16

P/E

ratio

115.29

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
1.32
3.86
3.69
4.41
3.6
8.09
8.27
7.59
14.21
18.24
21.97
13.75
18.46
24.6
20.53
17.45
21.29
Revenue per Share
0.61
0.09
0.33
0.32
0.36
0.48
1.1
0.29
0.3
0.74
0.76
0.43
0.34
0.44
0.34
1.71
0.3
Basic EPS, GAAP
-0.77
-0.13
-0.08
0.13
-0.1
0.08
0.12
0.05
4.98
0.42
0.33
-0.18
-0.08
1.46
-1.24
-0.49
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
4.12
4.2
4.52
4.83
5.17
6.7
7.8
8.09
8.39
9.15
9.91
10.35
10.63
11.19
11.54
13.25
- -
Book Value per Share
4.12
4.2
4.52
4.83
5.17
6.7
7.8
8.09
8.39
9.15
9.91
10.35
10.63
11.19
11.54
13.25
- -
Tangible Book Value per Share
16
16
16
16
16
16
16
16
16
16
16
16
16
16
16
16
16
Basic Weighted Avg Shares
22
63
60
72
59
132
135
124
231
297
358
224
300
400
334
284
343
Sales/Revenue/Turnover
46.49
3.89
14.32
11.13
8.24
8.11
17.36
5.18
2.85
4.77
3.32
4.04
2.46
1.04
1.4
1.33
1.49
Operating Margin (%)
2
2
2
2
3
3
3
3
4
4
4
4
4
4
4
3
3
Depreciation Expense
10
2
5
5
6
8
18
5
5
12
12
7
6
7
6
28
5
Net Income, GAAP
- -
6.44
19.05
20.59
20.16
20.2
22.34
19.98
19.39
17.55
35.31
31.19
29.33
18.04
24.22
19.24
41.06
Effective Tax Rate (%)
46.09
2.4
9.02
7.2
10.02
5.94
13.34
3.81
2.09
4.07
3.47
3.12
1.87
1.77
1.67
9.81
1.41
Profit Margin (%)
-18
-23
-18
-13
-6
19
35
39
34
48
67
78
86
99
107
152
- -
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
67
68
74
79
84
109
127
132
136
149
161
168
173
182
188
216
- -
Total Equity
14.33
2.63
7.15
6.07
3.49
7.21
13.74
3.53
3.51
7.35
5.7
3.62
2.94
1.86
1.86
11.69
- -
Return on Invested Capital (%)
14.21
1.74
5.57
6.09
6.81
7.63
14.55
4.1
4.08
8.34
7.86
4.28
3.36
4.07
3.09
12.74
- -
Return on Capital (%)
23.53
2.22
7.64
6.79
7.21
8.1
15.2
3.64
3.6
8.46
8.01
4.24
3.28
4
3.02
13.81
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
30
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
16
16
16
Market Capitalization
555
421
564

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
359
- -
Cash, Cash Equivalents & STI
- -
66
- -
Accounts Receivable, Net
- -
276
- -
Inventories
- -
40
- -
Total Current Liabilities
- -
207
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
30
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.15%
6.07%
14.82%
Free Cash Flow
680.63%
-498.7%
-60.2%
Net Income, GAAP
55.23%
68.25%
399.55%
Sales/Revenue/Turnover
12.85%
-0.29%
-14.99%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
84
24
142
84
334
2026
64
135
9
76
284
2027
124
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.1
0.01
0.1
0.12
0.34
2026
1.48
0.05
0.05
0.13
1.71
2027
0.07
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Biofil Chemicals and Pharmaceuticals Limited manufactures and trades pharmaceutical bulk drugs and chemicals in India through its Pharmaceutical and Chemicals divisions; it produces basic drugs including sodium chloride, potassium chloride, sodium citrate, diethyl carbamazine citrate, ferrous sulphate, dried ferrous sulphate, ferrous fumarate, micro crystalline cellulose, and dicyclomine hydrochloride; it also manufactures plastic drippers and caps for pharmaceutical packaging applications and provides job work services for pharmaceutical drug manufacturing. Incorporated in 1985 and headquartered at 11/12 Sector E, Sanwer Road Industrial Area, Indore, Madhya Pradesh, the company operates production facilities in Indore and Pithampur, Dhar district, primarily serving the Indian healthcare sector with 26 employees. Recent developments include the acquisition on July 24, 2025, of 335,888 equity shares in M. R. Organisation Limited, a tech-based last-mile utility services provider, increasing Biofil's stake to 64%; management changes feature Ketan Shah's appointment as Chairman and Managing Director on August 12, 2025, for three years and Smitesh Shah's appointment as Additional Promoter Non-Executive Non-Independent Director on August 23, 2025; the company reported standalone net profit after tax of Rs 34.86 crore for the quarter ended September 30, 2025.